For in vitro diagnostic use. Others D-DI2 IVD D-DI2 CPS_000066 Tina-quant D-Dimer Gen.2. 05077753190 D-Dimer Gen.2, 200Test, cobas c111 D-DI2 04015630924073 Reagents, kits 4 × 50 tests cobas c 111 true 08105626190 D-Dimer Gen.2,100Test,cobas c pack green D-DI2 07613336133668 Reagents, kits 100 tests cobas c 303/503/703 true 04912551190 D-Dimer Gen.2, 100Test, cobas c, Integra D-DI2 04015630922956 Reagents, kits 100 tests COBAS INTEGRA 400 Plus, cobas c 311/501/502 true 05172381190 D-Dimer Gen.2, 100Test, cobas c 701 D-DI2 04015630925292 Reagents, kits 100 tests cobas c 701/702 true 05078318001 D-DI2 Tina-quant D-Dimer Gen.2 en 7 FF0000000629690E FF000000007FF60E 05077753190 307 cobas c 111 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use In vitro test for the quantitative immunological determination of fibrin degradation products (D‑Dimer and X‑oligomers) in human plasma on the cobas c 111 system.LREFGaffney PJ. Fibrinolysis Supplement 2 1993;7:2-8.,LREFMatsuda M, Yoshidi N, Terukina S, et al. Fibrinogen 4. Current basic and clinical aspects. Amsterdam/New York/Oxford: Elsevier Science Publishers 1990;43-48. In conjunction with a non-high clinical probability assessment, a normal (FREFFibrinogen Equivalent Unit/mL) result excludes deep vein thrombosis (DVT) and pulmonary embolism (PE) with high sensitivity. en 08105626500 D-DI2 Tina-quant D-Dimer Gen.2 en 6 FF0000000718D60E FF00000004C2300E 08105626190 10299 cobas c 703 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useIn vitro test for the quantitative immunological determination of fibrin degradation products (D‑Dimer and X‑oligomers) in human plasma on cobas c systems.LREFGaffney PJ. Fibrinolysis Supplement 2 1993;7:2-8.,LREFFibrinogen 4. Current basic and clinical aspects. Matsuda M et al. Amsterdam/New York/Oxford: Elsevier Science Publishers, 1990:43-8.In conjunction with a non‑high clinical probability assessment, a normal (FREFFibrinogen Equivalent Unit/mL) result excludes deep vein thrombosis (DVT) and pulmonary embolism (PE) with high sensitivity. en 0004912551190COIN D-DI2 Tina-quant D-Dimer Gen.2 en 6 FF000000043E6A0E FF00000000EE5B0E 04912551190 302 COBAS INTEGRA 400 plus Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useIn vitro test for the quantitative immunological determination of fibrin degradation products (D‑Dimer and X‑oligomers)LREFGaffney PJ. Fibrinolysis Supplement 2 1993;7:2-8.,LREFFibrinogen 4. Current basic and clinical aspects. Matsuda M et al. Amsterdam/New York/Oxford: Elsevier Science Publishers, 1990:43-8. in human plasma on COBAS INTEGRA systems.In conjunction with a non‑high clinical probability assessment, a normal (FREFFibrinogen Equivalent Unit/mL) result excludes deep vein thrombosis (DVT) and pulmonary embolism (PE) with high sensitivity. en 04912551500 D-DI2 Tina-quant D-Dimer Gen.2 en 8 FF00000006D3C40E FF0000000035E40E 04912551190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 302 COBAS INTEGRA 400 plus Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useIn vitro test for the quantitative immunological determination of fibrin degradation products (D‑Dimer and X‑oligomers) in human plasma on cobas c and COBAS INTEGRA systems.LREFGaffney PJ. Fibrinolysis Supplement 2 1993;7:2-8.,LREFFibrinogen 4. Current basic and clinical aspects. Matsuda M et al. Amsterdam/New York/Oxford: Elsevier Science Publishers, 1990:43-8.In conjunction with a non‑high clinical probability assessment, a normal (FREFFibrinogen Equivalent Unit/mL) result excludes deep vein thrombosis (DVT) and pulmonary embolism (PE) with high sensitivity. en 0104912551190c501 D-DI2 Tina-quant D-Dimer Gen.2 en 7 FF0000000468240E FF0000000042FD0E 04912551190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use In vitro test for the quantitative immunological determination of fibrin degradation products (D‑Dimer and X‑oligomers) in human plasma on Roche/Hitachi cobas c systems.LREFGaffney PJ. Fibrinolysis Supplement 2 1993;7:2-8.,LREFFibrinogen 4. Current basic and clinical aspects. Matsuda M et al. Amsterdam/New York/Oxford: Elsevier Science Publishers, 1990:43-8. In conjunction with a non‑high clinical probability assessment, a normal (FREFFibrinogen Equivalent Unit/mL) result excludes deep vein thrombosis (DVT) and pulmonary embolism (PE) with high sensitivity. en 05172381500 D-DI2 Tina-quant D-Dimer Gen.2 en 7 FF00000006D4600E FF00000000FF580E 05172381190 2492 cobas c 702 310 cobas c 701 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useIn vitro test for the quantitative immunological determination of fibrin degradation products (D‑Dimer and X‑oligomers) in human plasma on cobas c systems.LREFGaffney PJ. Fibrinolysis Supplement 2 1993;7:2-8.,LREFMatsuda M, Yoshidi N, Terukina S, et al. Fibrinogen 4. Current basic and clinical aspects. Amsterdam/New York/Oxford: Elsevier Science Publishers 1990;43-48.In conjunction with a non‑high clinical probability assessment, a normal (FREFFibrinogen Equivalent Unit/mL) result excludes deep vein thrombosis (DVT) and pulmonary embolism (PE) with high sensitivity. en